PharmaVentures Corporate Advisory Appoints Ping Shek as Senior Director in Transactions

OXFORD, England, June 7, 2011 /PRNewswire/ --

PharmaVentures today announced the appointment of Ping Shek as Senior Director in the Transactions division of Corporate Advisory working on a number of key M&A and divestment mandates in the healthcare business sector.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Ping to PharmaVentures. Our Transactions division is currently working with a number of key companies in the life sciences sector, providing a comprehensive M&A and asset divestment service and has recently celebrated successes for a number of clients including UCB, Sanofi, Helsinn and Dow Chemical. Our client portfolio will benefit from this key appointment to the team."

Kevin Bottomley, Head of Transactions says "Ping brings substantial healthcare and investment banking experience into PharmaVentures and has a track record of mandate origination and transaction execution from his previous posts. His broad experience and knowledge will be invaluable to our clients looking to optimise business assets, engaging acquirers and ensuring rapid closure of deals at the best value."

Ping is a physics graduate from Oxford and has an MBA (with a distinction in Advanced Corporate Finance) from the London Business School. He has previously worked with investment bankers Morgan Stanley International, Lazard Brothers, JP Morgan, Monitor Group and the Anglo Chinese Group.

Note to Editors

About PharmaVentures

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. It produces the highly popular PharmaDeals(R) (http://www.pharmadeals.net) range of intelligence products including analysis tools and reports, as well as PharmaTelevision(R) , the world's first dedicated online pharmaceutical television channel (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

    
    For further information

    Fintan Walton, CEO
    +44(0)1865-332733
    odette.hodder@pharmaventures.com